Journal of Clinical and Aesthetic Dermatology最新文献

{"title":"A Clinician's Guide to Dupilumab-related Ocular Surface Disease.","authors":"Sandi Assaf, Peter Lio, James Q Del Rosso","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Atopic dermatitis (AD) commonly presents in both children and adults with pruritic, eczematous lesions that can have a substantial impact on quality of life. Current biologics approved for AD include dupilumab, an IL-4 receptor alpha inhibitor, tralokinumab, an IL-13 inhibitor, lebrikizumab, an IL-13 inhibitor, and nemolizumab, an IL-31 receptor alpha inhibitor. Dupilumab, tralokinumab, and lebrikizumab are highly effective in addressing the inflammatory response and reducing pruritus in AD patients via the IL-13 pathway, but are also associated with conjunctivitis and ocular surface disorders (OSD) in some patients, especially compared to other biologics that do not inhibit the activity of IL-4 and/or IL-13. For practitioners, it is important to be aware that OSD is a relatively common side effect but rarely causes problems severe enough to lead to cessation of treatment. This brief report provides guidance on screening and managment of OSD in patients with AD receiving anti-IL-4 and/or IL-13 treatment.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 5","pages":"26-28"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12175816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Condyloma HPV Typing: A Clinical Necessity?","authors":"Haowei Han, Faraz Yousefian, Ciaran Smythe, Clay J Cockerell, Mark Nestor","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 5","pages":"14-15"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12175817/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of IDEOM's Clinical Framework to Optimize Psoriatic Arthritis Care: A Cross-sectional Quality Improvement Study.","authors":"Gretchen D Ball, Hassan Hamade, Sarah Romanelli, Melissa P Zundell, Sangyoon Shin, Thami Senthilkumaran, Angela Lamb, Saakshi Khattri, Lourdes Perez-Chada, Joseph F Merola, Alice B Gottlieb","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 5","pages":"12-14"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12175815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tralokinumab as a Therapeutic Alternative for Dupilumab-associated Arthralgia in Atopic Dermatitis: A Multi-center Case Series.","authors":"Ana B W Greenberg, Mona Shahriari, Michael C Cameron, Michael Payette, Diego Ruiz Dasilva, Giovanni Damiani, Edward I Herman, Lindsay A Eminger, Naiem T Issa, Adrian Rodriguez, James Q Del Rosso, Youna Kang, Jeffrey M Cohen, Christopher G Bunick","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a chronic inflammatory skin condition that often requires systemic treatment to achieve optimal clinical outcomes. The clinical and immunological heterogeneity of AD necessitates the use of various therapies to maximize efficacy while minimizing adverse events (AEs). Dupilumab, the first biologic agent approved by the United States Food and Drug Administration (FDA) for moderate-to-severe AD, targets interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling pathways. Although effective, some patients experience dupilumab-associated musculoskeletal AEs, such as arthralgia, arthritis, or enthesitis, which may lead to discontinuation of treatment. Recent studies suggest that IL-4 inhibition disrupts T-cell populations, promoting a skewed T-helper 17 (Th17)-dominant immune response that may contribute to arthralgia. Switching to alternative therapies, such as tralokinumab-an IL-13-specific inhibitor-has shown promise in alleviating these AEs while maintaining control of AD signs and symptoms. Case reports indicate that patients with dupilumab-associated arthralgia have improved after switching to tralokinumab, suggesting the potential of tralokinumab as a safer alternative for these individuals. We present a series of 15 AD patients treated with tralokinumab following discontinuation of dupilumab due to arthralgia. All 15 patients achieved clear or nearly clear skin and demonstrated reductions in AD signs and symptoms as measured by Investigator's Global Assessment (IGA), body surface area of involvement (BSA), and/or patient reported measures of pruritus. Importantly, all patients experienced resolution of arthralgia without recurrence while on tralokinumab. These findings support the use of tralokinumab as an effective and safe alternative therapy for patients with dupilumab-induced arthralgia.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 5","pages":"16-19"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12175839/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selected Abstracts from RAPIDS Immuno-Dermatology Conference.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 5-6 Suppl 1","pages":"S24-S26"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12303368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144745956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hidden in Plain Sight: Accurately Diagnosing Skin Infections in Skin of Color.","authors":"Archana M Sangha","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 5-6 Suppl 1","pages":"S28-S29"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12303371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144745954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bilateral Submental Superficial Thrombophlebitis Following Hyaluronic Acid Filler Injections.","authors":"Maria Hawkins","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Superficial thrombophlebitis is an uncommon but notable complication following dermal filler injections. This case highlights a 39-year-old female individual presenting with bilateral submental superficial thrombophlebitis following hyaluronic acid filler to the jawline and chin. To the author's knowledge, this is the first reported case of superficial venous thrombosis (SVT) in the neck following dermal filler injection. This report uniquely highlights longitudinal follow-up, ultrasound imaging documentation, and outcome, making it the first case documented in such detail. Through clinical evaluation and a multidisciplinary approach to management, this case emphasizes the importance of diagnosis and continued follow-up when addressing rare complications in aesthetic medicine.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 5-6 Suppl 1","pages":"S38-S39"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12303369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144745953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety Evaluation of Topical Products Containing Live Cultures and Ferment of Cutibacterium Acnes Subspecies Defendens Strain XYCM42 in Individuals Predisposed to Acne Vulgaris.","authors":"Mona L Alqam, Brian C Jones, Thomas M Hitchcock","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>For individuals with acne-prone skin, identifying a topical regimen that does not lead to progression of their inflammatory issues often poses a challenge. A topical skin probiotic regimen containing a specific strain of <i>Cutibacterium acnes (C. acnes)</i> subspecies <i>defendens</i>, XYCM42, has been shown to be beneficial in improving skin health and appearance in individuals with generally healthy skin, but the use of the skin probiotic has not been sufficiently assessed in individuals with acne-prone skin.</p><p><strong>Objective: </strong>The purpose of this study was to evaluate the safety and efficacy of daily application of a topical skin biome care regimen containing a living <i>C. acnes</i> subsp. <i>defendens</i> derivative strain, XYCM42, its ferment, and adjunct topicals in individuals with acne-prone skin.</p><p><strong>Methods: </strong>This eight-week study was conducted at five locations and included 136 total participants. At baseline, Week 1, Week 4, and Week 8, subjects completed product questionnaires and symptom severity surveys. Of the study subjects, 20 were enrolled for clinical efficacy evaluation at all timepoints. Clinical assessments included blemish lesion counts, Investigator's Global Assessment (IGA) of acne lesion severity, and clinical grading of skin cosmetic and safety parameters.</p><p><strong>Results: </strong>As early as Week 1 of regimen application, clinical observations demonstrated statistically significant improvements in acne severity scores, with no subjects reporting increased or worsened acne during the study. By Week 4, subjects showed significant changes in nearly all skin cosmetic parameters assessed, including skin texture, clarity, tone, fine wrinkling, undereye dark circles, dryness, and erythema. Lesion counts were significantly reduced from baseline at all timepoints, with 100 percent of subjects experiencing fewer non-inflammatory lesions and 70 percent and 30 percent with fewer papule and pustule inflammatory lesions, respectively, by the end of the study. No adverse events were reported.</p><p><strong>Conclusion: </strong>This at-home use study demonstrates that use of the XYCM42-based topical skin biome care regimen is both safe and appropriate for individuals with acne-prone skin. More broadly, the outcomes of this study provide further support toward the beneficial and commensal nature of <i>C. acnes</i> subsp. <i>defendens</i> in promoting skin health.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 5","pages":"44-53"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12175840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Treatment of Pembrolizumab-Induced Pruritus with Topical Roflumilast Cream 0.3% Once Daily.","authors":"Laura Lomax","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Pembrolizumab is an immune checkpoint inhibitor that is used in the treatment of various cancers. The reported mode of action of pembrolizumab is via binding to the PD-1 receptor which leads to blocking both immune-suppressing ligands, PD-L1 and PD-L2, from interacting with PD-1 to modulate the immune response. A common side effect of immune checkpoint inhibitors is pruritus, reported to occur in 14 to 47 percent of patients, which often reduces overall quality of life. This case report chronicles a patient suffering from significant pruritus and a lichenoid skin eruption after initiation of pembrolizumab treatment that was refractory to topical corticosteroid therapy, narrow band ultraviolet B light, and application of emollients. A topical phosphodiesterase-4 (PDE-4) inhibitor, roflumilast cream 0.3%, was subsequently initiated. Roflumilast is a selective inhibitor of PDE-4, approved by the United States Food and Drug Administration (FDA) in a 0.3% cream vehicle in 2022 for treatment of plaque psoriasis of any severity, and in a 0.3% foam vehicle in 2023 for treatment of seborrheic dermatitis of any severity. In 2024, roflumilast was FDA-approved in a 0.15% cream vehicle for treatment of mild-to-moderate atopic dermatitis in patients six years of age and older. In this adult patient, pruritus was improved within 48 hours after initiation of roflumilast cream 0.3% applied once daily and continued to be effective with use over time.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 5","pages":"36-37"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12175818/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Topical Corticosteroid Use in Everyday Clinical Practice: Cautionary Tales.","authors":"Melodie Young","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Despite the development of advanced targeted topical treatments for chronic inflammatory skin diseases and recent calls for caution when prescribing topical corticosteroids (TCS), TCS continue to be the most prescribed dermatologic agent. Yet the perception that adverse effects are uncommon with TCS use persists. To combat this misperception, I selected examples of patients from my practice that illustrate the real-world risks associated with TCS use. This case series provides several key clinical pearls for managing TCS use in everyday clinical practice including: 1) Even using TCS for short periods and as prescribed is not without risks. 2) Long-term TCS use (even intermittent use) can result in permanent skin changes that can even outlast the disease the TCS was used to treat. 3) TCS overuse can have serious adverse effects resulting in hospitalization, including adrenal suppression, infection, and even sepsis. 4) Patients who are dissatisfied with older TCS-sparing treatments might continue to seek more potent TCS, resulting in doctor/clinic hopping and potential TCS misuse. 5) Patients might repurpose TCS prescriptions for other body areas, leading to high-potency TCS being applied to thin-skinned areas and irreversible skin damage.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"18 5-6 Suppl 1","pages":"S20-S22"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12303370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144745957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}